SCHEMBL12401768

SCHEMBL12401768

COc1c(Cl)cc(C(C)(C)C)cc1CN1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 5/20 0.43
TSHR P16473 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX15 P16050 1/20 0.41
HIF1A Q16665 1/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 3/20 0.40
GAA P10253 2/20 0.39
XBP1 P17861 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104438 0.86 ALDH1A1 (0.49) CACNA1BALDH1A1TSHRMEN1KMT2A
SCHEMBL10104443 0.84 ALDH1A1 (0.47) CACNA1BSMN1; SMN2ALDH1A1TSHRMEN1
SCHEMBL5118355 0.82 CACNA1B (0.43) CACNA1BALDH1A1TSHRMEN1KMT2A
SCHEMBL13130588 0.80 MAPK1 (0.43) CACNA1BALDH1A1TSHRMEN1KMT2A
SCHEMBL12407101 0.78 MEN1 (0.43) SMN1; SMN2ALDH1A1TSHRMEN1KMT2A
SCHEMBL12852063 0.77 CACNA1B (0.52) CACNA1BSMN1; SMN2ALDH1A1TSHRKDM4E
SCHEMBL5118350 0.76 POLB (0.42) CACNA1BSMN1; SMN2ALDH1A1TSHRMEN1
SCHEMBL17916107 0.75 KDM4E (0.52) CACNA1BSMN1; SMN2ALDH1A1TSHRKDM4E
SCHEMBL10104440 0.72 CYP2A13 (0.47) SMN1; SMN2KDM4ECYP3A4POLBHTT
SCHEMBL12401769 0.72 CYP2C19 (0.53) ALDH1A1TSHRMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 US disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 US disclosed
US-7964624-B1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 CACNA1B 3508/4885SMN1; SMN2 2156/4885ALDH1A1 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.